Nanomedical Diagnostics' Agile R100 Detects Zika

Nanomedical Diagnostics, a Serra Capital II portfolio company, has announced a new publication in Biosensors and Bioelectronics demonstrating detection of Zika viral antigen using their label-free Agile R100 biosensor.  Nano is a cutting-edge life science company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development.

The Zika virus, a mosquito-borne infection, has been shown to be a cause of microcephaly and other severe fetal brain defects. For pregnant women, it is especially important to reliably identify Zika virus infection in a timely manner, but current methods show high false positive rates and can take weeks to return test results. The compact and portable Agile R100 represents a potential methodology to identify Zika infection promptly.